Contemporary definitions of tumor specific antigens, immunogens and markers as related to the adaptive responses of the cancer-bearing host

Anticancer Research

Volumn 25, Issue 3 C, 2005, Pages 2345-2355

  Coggin Jr , Joseph H ^a   Barsoum, Adel L ^a   Rohrer, James W ^a   Thurnher, Martin ^b   Zeis, Matthias ^c  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

Cancer bearing host; Immunogens; Review; Tumor markers; Tumor specific antigens

Indexed keywords

ABELSON KINASE; ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CHAPERONE; GLYCOPROTEIN GP 96; IMMATURE LAMININ RECEPTOR PROTEIN; MUCIN 1; ONCOFETAL ANTIGEN; RECOMBINANT ANTIGEN; TUMOR MARKER; TUMOR REJECTION ANTIGEN; TUMOR SPECIFIC TRANSPLANTATION ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADENOVIRUS; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COMPLEX FORMATION; CYTOTOXIC T LYMPHOCYTE; HOST RESISTANCE; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIMIAN VIRUS 40; T LYMPHOCYTE ACTIVATION; THYROID CARCINOMA; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TERMINOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 22944436812     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Cibotti R, Kanellopoulos JM, Cabaniols JP, Halle-Panenko O, Kosmatopoulos K, Sercarz E and Kourilsky P: Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. PNAS 89: 416-420, 1992.
2. Nanda NK and Sercarz EE: Induction of anti-self-immunity to cure cancer. Cell 82: 13-17, 1995.
3. Restifo NP: Hierarchy, tolerance and dominance in the antitumor T-cell response. J Immunother 24: 193-194, 2001.
4. Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH and Economou JS: Generation of human T-cell responses to an HLA-A2.2-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 59: 3134-3142, 1999.
5. Dorland WA Newmann: Dorland's Illustrated Medical Dictionary. Philadelphia, W.B. Saunders Company, pp. 1940, 2003.
6. Abbas AK and Lichtman AH: Basic Immunology: Functions and Disorders of the Immune System. 1st Edition, Philadelphia, W.B. Saunders Company, pp. 184, 2001.
7. Janeway CA Jr, Travers P, Hunt S and Walport M: Immunobiology: The Immune System in Health and Disease. New York and London, Garland, 1997, G-2-G-3.
8. Payne WJ Jr and Coggin JH Jr: Mouse monoclonal antibody to embryonic antigen: development, cross-reactivity with rodent and human tumors, and preliminary polypeptide characterization. J Natl Cancer Inst 75: 527-544, 1985.
9. Gussack GS, Rohrer SD, Hester RB, Liu PI and Coggin JH Jr: Human squamous cell carcinoma lines express oncofetal 44-kD polypeptide defined by monoclonal antibody to mouse fetus. Cancer 62: 283-290, 1988.
10. Rohrer JW, Barsoum AL and Coggin JH Jr: The development of a new universal tumor rejection antigen expressed on human and rodent cancers for vaccination and prevention of cancer and in tumor therapy. MAI 1: 191-195, 2001.
11. Barsoum AL, Rohrer JW and Coggin JH Jr: 37kDa oncofetal antigen is an autoimmunogenic homologue of the 37kDa laminin receptor precursor. Cell Biol Mol Lett 5: 207-230, 2000.
12. Coggin JH Jr, Barsoum AL and Rohrer JW: 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers. Anticancer Res 19: 5535-5542, 1999.
13. Coggin JH Jr, Barsoum AL and Rohrer JW: Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen. Immunol Today 19: 405-408, 1998.
14. Rohrer JW, Rohrer SD, Barsoum AL and Coggin JH Jr: Differential recognition of murine tumor-associated oncofetal transplantation antigen and individually specific tumor transplantation antigens by syngeneic cloned BALB/c and RFM mouse T cells. J Immunol 152: 754-764, 1994.
15. Coggin JH: Shared cross-protective OFAs on chemically induced rodent sarcomas. Immunol Today 10: 76-78, 1989.
16. Coggin JH Jr: Oncofetal antigens. Nature 319: 428, 1986.
17. Coggin JH Jr, Rohrer SD, Hester RD, Barsoum AL, Rashid HU and Gussack GS: 44-kd oncofetal transplantation antigen in rodent and human fetal cells. Implications of recrudescence in human and rodent cancers. Arch Otolaryngol Head Neck Surg 119: 1257-1266, 1993.
18. Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA and Economou JS: Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 59: 3064-3067, 1999.
19. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH and Economou JS: T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 166: 5300-5308, 2001.
20. Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH and Economou JS: Alpha-fetoprotein-specific tumor immunity induced by plasmid prime adenovirus boost genetic vaccination. Cancer Res 61: 8782-8786, 2001.
21. Berinstein NL: Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 20: 2197-2207, 2002.
22. Rohrer SD, Sarli RN, Barsoum AL, Hester RB and Coggin JH Jr: Expression of 44-kilodalton oncofetal antigen as a premalignancy marker in X irradiation-induced murine T-cell lymphoma. J Natl Cancer Inst 84: 602-609, 1992.
23. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwieck D, Gilboa E and Vieweg J: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63: 2127-2133, 2003.
24. Foley EJ: Antigen properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13: 835-837, 1953.
25. Klein G, Sjögren HO, Klein E and Hellström KE: Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autchthonous host. Cancer Res 20: 1561-1572, 1960.
26. Prehn RT and Main JM: Immunity to methylcholanthrene-induced sarcomas. JNCI 18: 769-778, 1957.
27. Baldwin RW: Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of the implanted tumours. Br J Cancer 9: 652-657, 1955.
28. Melief CJ: Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 58: 143-175, 1992.
29. Ambrose KR, Anderson NG and Coggin JH: Interruption of SV40 oncogenesis with human foetal antigen. Nature 233: 194-195, 1971.
30. Levine AJ, Momand J and Finlay CA: The p53 tumour-suppressor gene. Nature 351: 453-456, 1991.
31. Smyth MJ and Trapani JA: Lymphocyte-mediated immunosurveillance of epithelial cancers? Trends Immunol 22: 409-411, 2001.
32. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998, 2002.
33. Ortegel JW, Staren ED, Faber LP, Warren WH and Braun DP: Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma. Cancer Immunol Immunother 48: 627-634, 2000.
34. Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M and Rosenberg SA: Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol 169: 6036-6047, 2002.
35. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR and June CH: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772, 2001.
36. Alexander-Miller MA, Leggatt GR and Berzofsky JA: Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. PNAS 93: 4102-4107, 1996.
37. Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, Cassidanius A, Lemarre P, Billaudel S, Labarriere N and Jotereau F: Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 51: 539-546, 2002.
38. Labarriere N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dreno B and Jotereau F: Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 51: 532-538, 2002.
39. Chiu PP, Ivakine E, Mortin-Toth S and Danska JS: Susceptibility to lymphoid neoplasia in immunodeficient strains of nonobese diabetic mice. Cancer Res 62: 5828-5834, 2002.
40. Tremblay F, Fernandes M, Habbab F, Edwardes MD, Loertscher R and Meterissian S: Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol 9: 785-788, 2002.
41. Rohrer JW, Barsoum AL, Dyess DL, Tucker JA and Coggin JH Jr: Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. J Immunol 162: 6880-6892, 1999.
42. Rohrer JW and Coggin JH Jr: CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol 155: 5719-5727, 1995.
43. Rohrer JW, Culpepper C, Barsoum AL and Coggin JH Jr: Characterization of RFM mouse T lymphocyte anti-oncofetal antigen immunity in apparent tumor-free, long-term survivors of sublethal X-irradiation by limiting dilution T lymphocyte cloning. J Immunol 154: 2266-2280, 1995.
44. Coggin JH Jr, Barsoum AL, Rohrer JW, Tucker JA and Dyess DL: Materno-fetal immunobiology hypothesis: immature laminin receptor protein is a primitive, species conserved, universal embryonic T and B cell immunogen providing both maternal and fetal protection. MAI 2: 84-91, 2001.
45. Hu HM, Winter H, Ma J, Croft M, Urba WJ and Fox BA: CD28, TNF receptor and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8(+) T cells. J Immunol 169: 4897-4904, 2002.
46. Shen X, Wong SB, Buck CB, Zhang J and Siliciano RF: Direct priming and cross-priming contribute differentially to the induction of CD8(+) CTL following exposure to Vaccinia virus via different routes. J Immunol 169: 4222-4229, 2002.
47. Zinkernagel RM: On cross-priming of MHC class I-specific CTL: rule or exception? Eur J Immunol 32: 2385-2392, 2002.
48. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D and Levitsky H: The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188: 2357-2368, 1998.
49. Appay V: CD4+ cytotoxic T lymphocytes. MAI 2: 200, 2002.
50. Segal BM, Glass DD and Shevach EM: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol 168: 1-4, 2002.
51. Baldwin RW, Glaves D and Vose BM: Embryonic antigen expression in chemically induced rat hepatomas and sarcomas. Int J Cancer 10: 233-243, 1972.
52. Prehn RT: Stimulatory effects of immune reactions upon the growths of untransplanted tumors. Cancer Res 54: 908-914, 1994.
53. Ting CC, Larvin DH, Shiu G and Herberman RB: Expression of fetal antigens in tumor-cells. PNAS 69: 1664-1668, 1972.
54. Srivastava PK and Old LJ: Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 9: 78-83, 1988.
55. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX and Schreiber H: Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17: 737-747, 2002.
56. Prehn RT and Prehn LM: Immunostimulation of cancer versus immunosurveillance. Medicina (B Aires) 56(Suppl 1): 65-73, 1996.
57. Robbins PF and Kawakami Y: Human tumor antigens recognized by T cells. Curr Opin Immunol 8: 628-636, 1996.
58. Schott M, Seissler J, Lettman M, Fouxon V, Scherbaum WA and Feldkamp J: Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 86: 4965-4969, 2001.
59. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P and Zanetti M: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. PNAS 97: 4796-4801, 2000.
60. Fisk B, Blevins TL, Wharton JT and Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109-2117, 1995.
61. Keogh E, Filkes J, Southwood S, Celis E, Chesnut R and Sette A: Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201- binding affinity. J Immunol 167: 787-796, 2001.
62. Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA and Kosmatopoulos K: Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol 31: 3261-3270, 2001.
63. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA and Kosmatopoulos K: HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168: 5900-5906, 2002.
64. Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA and Yang JC: High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162: 989-994, 1999.
65. Sykulev Y, Joo M, Vturina I, Tsomides TJ and Eisen HN: Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4: 565-571, 1996.
66. Liu K, Schoonmaker MM, Levine BL, June CH, Hodes RJ and Weng NP: Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. PNAS 96: 5147-5152, 1999.
67. Lollini P-L and Forni G: Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol Immunother 51: 409-416, 2002.
68. Ward S, Casey D, Labarthe M-C, Whelan M, Dalgleish A, Pandha H and Todryk S: Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother 51: 351-357, 2002.
69. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188: 22-32, 2002.
70. Carswell EA, Wanebo HJ, Old LJ and Boyse EA: Immunogenic properties of reticulum cell sarcomas of SJL/J mice. JNCI 44: 1281-1288, 1970.
71. Kripke ML: Immunology mechanisms in U.V. radiation carcinogenesis. Adv Cancer Res 34: 69-106, 1988.
72. Morton DL, Miller GF and Wood DA: Demonstration of tumor-specific immunity against antigens unrelated to the mammary tumor virus in spontaneous mammary adenocarcinomas. JNCI 42: 289-301, 1969.
73. Afar De, McLaughlin J, Sherr CJ, Witte ON and Roussel MF: Signaling by ABL oncogenes through cyclin D1. PNAS 92: 9540-9544, 1995.
74. Frew IJ, Dickens RA, Cuddihy AR, Del Rosario M, Reinhard C, O'Connell MJ and Bowtell DD: Normal p53 function in primary cells deficient for Siah genes. Mol Cell Biol 22: 8155-8164, 2002.
75. Niu ZS, Li BK and Wang M: Expression of p53 and C-myc genes and its clinical relevance in the hepatocellular carcinomatous and pericarcinomatous tissues. World J Gastroenterol 8: 822-826, 2002.
76. Daemen T, Regts J, Holtrop M and Wilschut J: Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther 9: 85-94, 2002.
77. Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski TF and Leo O: Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 81: 428-437, 1999.
78. Rickinson AB and Moss DJ: Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15: 405-431, 1997.
79. Schell TD and Tevethia SS: Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD(+) T lymphocytes by the endogenous tumor antigen. J Immunol 167: 6947-6956, 2001.
80. Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z, Clark B, De Pascalis R, Schlom J and Van Waes C: Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res 62: 5049-5057, 2002.
81. Schmitz J, Reali E, Hodge JW, Patel A, Davis G, Schlom J and Greiner JW: Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing CEA transgenic mice. Cancer Res 62: 5058-5064, 2002.
82. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
83. Vonderheide RH, Hahn WC, Schultze JL and Nadler LM: The tolemerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673-679, 1999.
84. Brichard V, Van Pel A, Wolfel T, Volfel C, De Plaen E, Lethe B, Coulie P and Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178: 489-495, 1993.
85. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF and Slingluff CL Jr: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719, 1994.
86. Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ and Figdor CG: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179: 1005-1009, 1994.
87. Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G and Lotze MT: Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 181: 363-368, 1995.
88. Wang RF, Robbins PF, Kawakami Y, Kang XQ and Rosenberg SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181: 799-804, 1995.
89. Srivastava P: Interaction of heast shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20: 395-425, 2002.
90. Srivastava P: Heat-shock proteins. MAI 2: 104, 2002.
91. Udono H and Srivastava PK: Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 152: 5398-5403, 1994.
92. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ and Srivastava PK: Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 88: 232-238, 2000.
93. Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombarde C, Arienti F, Marchiano A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P and Parmiani G: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20: 4169-4180, 2002.
94. Patton S, Gendler S and Spicer A: The epithelial mucin, MUC1 of milk, mammary gland and other tissues. Biochim Biophys Acta 1241: 407-424, 1995.
95. Ho S, Niehans G, Lyftogt C, Yan P, Cherwitz D and Gum E: Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 53: 641-651, 1993.
96. Carr-Brendel V, Markovic D, Ferrer K, Smith M, Taylor-Papadimitriou J and Cohen EP: Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1. Cancer Res 60: 2435-2443, 2000.
97. Mukherjee P, Ginardi AR, Madsen CS, Sterner CJ, Adriance MC, Tevethia MJ and Gendler SJ: Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol 165: 3451-3460, 2000.
98. Butschak G and Karsten U: Isolation and characterization of thomsen-friedenreich-specific antibodies from human serum. Tumour Biol 23: 113-122, 2002.